Searchable abstracts of presentations at key conferences in endocrinology

ea0087p3 | Poster Presentations | UKINETS2022

Manipulating the composition of the culture medium promotes neuroendocrine cell differentiation in mouse and human gastric organoids

Exarchou Klaire , Duckworth Carrie , Stephens Nathan , Howes Nathan , Mark Pritchard David

Aim: Organoid cultures are a powerful model system for the study of cell biology and human disease. Manipulation of the composition of the culture medium has been used to promote cellular differentiation in gastric organoids to allow more accurate modelling of the mature epithelial cells present in the stomach. However, methods to promote the differentiation of neuroendocrine cells and specifically enterochromaffin-like (ECL)-cells within a gastric organoid system have not yet...

ea0068p1 | Abstracts | UKINETS2019

Size still matters for appendiceal neuroendocrine tumours (aNETs)

Alabraba Edward , Malik Hassan , Banks Melissa , Pritchard Mark , Cuthbertson Daniel , Poston Graeme , Fenwick Stephen

Background: Appendiceal neuroendocrine tumours (aNETs) are usually diagnosed incidentally at appendicectomy, are indolent and rarely recur.Methods: We retrospectively analysed patients diagnosed with aNETs and entered prospectively into our tertiary referring centre’s NET database between 1990 and 2016.Results: 102 patients (F:M ratio of 1.04:1) presented with aNET at a median age of 39.4 (range 16.3–81.1) years. Average ...

ea0068p4 | Abstracts | UKINETS2019

Appendiceal GCCs have a poor prognosis despite completion surgery as recommended by ENET guidelines

Alabraba Edward , Malik Hassan , Banks Melissa , Pritchard Mark , Cuthbertson Daniel , Poston Graeme , Fenwick Stephen

Background: Current ENET guidelines inform our management of GCCs but we still have poor understanding of how these tumours behave in clinical practice.Methods: We retrospectively analysed patients diagnosed with GCCs and entered prospectively into our tertiary referring centre’s NET database between 1990 and 2016.Results: 41 patients (F:M ratio of 1.28:1) presented with GCC at a median age of 61 (range 27–79) years. Aver...

ea0038p334 | Pituitary | SFEBES2015

Clinically non-functioning pituitary macroadenomas: presenting features and outcomes: recent experience at a tertiary centre

Yadagiri Mahender , Vijay Arun , Pritchard Mark , Nayak Ananth , Shaw Simon , Saravanappa Natarajan , Ayuk John , Jose Biju

Introduction: Non-functioning pituitary macroadenoma (NFMA) can cause considerable morbidity due to pituitary dysfunction and pressure effects. We present recent experience in managing cases diagnosed with NFMA at a single tertiary centre between January 2009 and October 2013.Results: Of the 63 patients with NFMA, 28 (44%) were females. Age ranged from 22 to 91 (mean 63). Visual disturbance symptoms (35/63; 57%) were the commonest presentation. Headache ...

ea0087p2 | Poster Presentations | UKINETS2022

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Khan Mohid , Davies Louise , Back Melissa , Shah Tahir , Pritchard Mark , Cook Kathryn , Hull Diana , McKane Gail , Day Melissa , Grandoulier Anne-Sophie , Higgs Kate

Introduction: LAN, a somatostatin analogue, is a common first-line treatment for NETs. LAN comes as a pre-filled, ready-to-use syringe, administered every 4 weeks. In the UK, patients may receive LAN at home. The aim of PREF-NET was to generate real-world evidence describing patient’s experience of LAN administered in homecare and hospital settings, and the associated impact of treatment setting on other areas of patients’ lives.Methods: PREF-N...

ea0060p30 | (1) | UKINETS2018

The impact of 68Ga-based PET-CT scanning on the management of patients with familial pancreatic neuroendocrine tumours (panNETs)

Cuthbertson Daniel , Barriuso Jorge , Pizanias Michail , Jaffa Matthew , Nuttall Christina , Vivian Gillian , Halloran Tom , Westwood Tom , Prachalias Andreas , Lalloo Fiona , Weismann Hulya , Martin Wendy , Vinjamuri Sobhan , Mark Pritchard D. , Fenwick Steve , Ganeh Paula , Raraty Mike , McNamara Mairead , Srirajaskanthan Raj , Ramage John , Manoharan Prakash , Yip Vincent

Background: Pancreatic neuroendocrine tumours (panNETs) may arise as part of an underlying genetic condition such as multiple endocrine neoplasia type 1 (MEN type 1). The value of functional imaging using 68Ga-labelled synthetic octreotide analogues using PET-CT has not been extensively evaluated in patients with MEN1 to determine its value.Methods: We investigated the effect of 68Ga-based PET-CT imaging on patient management in pat...